Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Treasury Shares (2021 - 2026)

Rani Therapeutics Holdings' Treasury Shares history spans 6 years, with the latest figure at $225313.0 for Q1 2026.

  • On a quarterly basis, Treasury Shares fell 65.49% to $225313.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $225313.0, a 65.49% decrease, with the full-year FY2025 number at $348702.0, up 10606.23% from a year prior.
  • Treasury Shares came in at $225313.0 for Q1 2026, down from $348702.0 in the prior quarter.
  • The five-year high for Treasury Shares was $996500.0 in Q1 2022, with the low at $3257.0 in Q4 2024.
  • Historically, Treasury Shares has averaged $430648.8 across 5 years, with a median of $382503.5 in 2025.
  • Biggest five-year swings in Treasury Shares: tumbled 90.3% in 2024 and later soared 10606.23% in 2025.
  • Year by year, Treasury Shares stood at $67389.0 in 2022, then tumbled by 50.16% to $33586.0 in 2023, then plummeted by 90.3% to $3257.0 in 2024, then surged by 10606.23% to $348702.0 in 2025, then plummeted by 35.39% to $225313.0 in 2026.
  • Business Quant data shows Treasury Shares for RANI at $225313.0 in Q1 2026, $348702.0 in Q4 2025, and $416305.0 in Q3 2025.